Literature DB >> 30100775

Current approaches and future directions in the treatment of leprosy.

Sophie M Worobec1.   

Abstract

This review surveys current treatments and future treatment trends in leprosy from a clinical perspective. The World Health Organization provides a multidrug treatment regimen that targets the Mycobacterium leprae bacillus which causes leprosy. Several investigational drugs are available for the treatment of drug-resistant M. leprae. Future directions in leprosy treatment will focus on: the molecular signaling mechanism M. leprae uses to avoid triggering an immune response; prospective studies of the side effects experienced during multiple-drug therapy; recognition of relapse rates post-completion of designated treatments; combating multidrug resistance; vaccine development; development of new diagnostic tests; and the implications of the recent discovery of a genetically distinct leprosy-causing bacillus, Mycobacterium lepromatosis.

Entities:  

Keywords:  Hansen’s disease; epidemiology; leprosy; multidrug resistance; multidrug therapy

Year:  2012        PMID: 30100775      PMCID: PMC6067781          DOI: 10.2147/RRTM.S27395

Source DB:  PubMed          Journal:  Res Rep Trop Med        ISSN: 1179-7282


  45 in total

Review 1.  An update on the diagnosis and treatment of leprosy.

Authors:  Samuel L Moschella
Journal:  J Am Acad Dermatol       Date:  2004-09       Impact factor: 11.527

2.  Treatment of recurrent erythema nodosum leprosum with infliximab.

Authors:  William R Faber; Annigje J Jensema; Wouter F M Goldschmidt
Journal:  N Engl J Med       Date:  2006-08-17       Impact factor: 91.245

3.  Case of diffuse lepromatous leprosy associated with "Mycobacterium lepromatosis".

Authors:  Lucio Vera-Cabrera; Wendy G Escalante-Fuentes; Minerva Gomez-Flores; Jorge Ocampo-Candiani; Philippe Busso; Pushpendra Singh; Stewart T Cole
Journal:  J Clin Microbiol       Date:  2011-10-19       Impact factor: 5.948

4.  Effects of freezing and thawing on the viability and the ultrastructure of in vivo grown mycobacteria.

Authors:  F Portaels; K Fissette; K De Ridder; P M Macedo; A De Muynck; M T Silva
Journal:  Int J Lepr Other Mycobact Dis       Date:  1988-12

5.  The activity of several newer antimicrobials against logarithmically multiplying M. leprae in mice.

Authors:  Jasmin Burgos; Eduardo de la Cruz; Rose Paredes; Cora Revelyn Andaya; Robert H Gelber
Journal:  Lepr Rev       Date:  2011-09       Impact factor: 0.537

6.  Comparative sequence analysis of Mycobacterium leprae and the new leprosy-causing Mycobacterium lepromatosis.

Authors:  Xiang Y Han; Kurt C Sizer; Erika J Thompson; Juma Kabanja; Jun Li; Peter Hu; Laura Gómez-Valero; Francisco J Silva
Journal:  J Bacteriol       Date:  2009-07-24       Impact factor: 3.490

7.  A clinical and immunological study of four babies of mothers with lepromatous leprosy, two of whom developed leprosy in infancy.

Authors:  M E Duncan; R Melsom; J M Pearson; S Menzel; R S Barnetson
Journal:  Int J Lepr Other Mycobact Dis       Date:  1983-03

8.  The frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed leprosy patients from Myanmar, Indonesia and the Philippines.

Authors:  Masanori Matsuoka; Teky Budiawan; Khin Saw Aye; Kyaw Kyaw; Esterlina Virtudes Tan; Eduardo Dela Cruz; Robert Gelber; Paul Saunderson; Victoria Balagon; Vijaykumar Pannikar
Journal:  Lepr Rev       Date:  2007-12       Impact factor: 0.537

9.  MicroRNA-21 targets the vitamin D-dependent antimicrobial pathway in leprosy.

Authors:  Philip T Liu; Matthew Wheelwright; Rosane Teles; Evangelia Komisopoulou; Kristina Edfeldt; Benjamin Ferguson; Manali D Mehta; Aria Vazirnia; Thomas H Rea; Euzenir N Sarno; Thomas G Graeber; Robert L Modlin
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

10.  Ancient skeletal evidence for leprosy in India (2000 B.C.).

Authors:  Gwen Robbins; V Mushrif Tripathy; V N Misra; R K Mohanty; V S Shinde; Kelsey M Gray; Malcolm D Schug
Journal:  PLoS One       Date:  2009-05-27       Impact factor: 3.240

View more
  6 in total

Review 1.  Natural-Product-Based Solutions for Tropical Infectious Diseases.

Authors:  Oyelola Adegboye; Matt A Field; Andreas Kupz; Saparna Pai; Dileep Sharma; Michael J Smout; Phurpa Wangchuk; Yide Wong; Claire Loiseau
Journal:  Clin Microbiol Rev       Date:  2021-09-08       Impact factor: 50.129

Review 2.  Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies.

Authors:  Thomas J Hwang; Svetlana Dotsenko; Azizkhon Jafarov; Karin Weyer; Dennis Falzon; Kaspars Lunte; Paul Nunn; Ernesto Jaramillo; Salmaan Keshavjee; Douglas F Wares
Journal:  BMJ Open       Date:  2014-01-02       Impact factor: 2.692

3.  Unexpectedly high leprosy seroprevalence detected using a random surveillance strategy in midwestern Brazil: A comparison of ELISA and a rapid diagnostic test.

Authors:  Marco Andrey C Frade; Natália A de Paula; Ciro M Gomes; Sebastian Vernal; Fred Bernardes Filho; Helena B Lugão; Marilda M M de Abreu; Patrícia Botini; Malcolm S Duthie; John S Spencer; Rosa Castália F R Soares; Norma T Foss
Journal:  PLoS Negl Trop Dis       Date:  2017-02-23

4.  A novel integrated molecular and serological analysis method to predict new cases of leprosy amongst household contacts.

Authors:  Rafael Silva Gama; Márcio Luís Moreira de Souza; Euzenir Nunes Sarno; Milton Ozório de Moraes; Aline Gonçalves; Mariane M A Stefani; Raúl Marcel González Garcia; Lucia Alves de Oliveira Fraga
Journal:  PLoS Negl Trop Dis       Date:  2019-06-10

5.  Prospects for new leprosy diagnostic tools, a narrative review considering ELISA and PCR assays.

Authors:  Rafael Silva Gama; Lázaro Azevedo Leite; Lívia Tavares Colombo; Lúcia Alves de Oliveira Fraga
Journal:  Rev Soc Bras Med Trop       Date:  2020-11-25       Impact factor: 1.581

Review 6.  Protective Efficacy of BCG Vaccine against Mycobacterium leprae and Non-Tuberculous Mycobacterial Infections.

Authors:  Davit Orujyan; William Narinyan; Subhapradha Rangarajan; Patrida Rangchaikul; Chaya Prasad; Beatrice Saviola; Vishwanath Venketaraman
Journal:  Vaccines (Basel)       Date:  2022-03-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.